Literature DB >> 10375387

Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management.

J L Januzzi1, I K Jang.   

Abstract

Heparin-induced thrombocytopenia (HIT) may be complicated by severe thrombotic complications and death. Currently no specific laboratory test is available to make the diagnosis. When HIT is clinically suspected, heparin should be discontinued immediately. While no specific therapy for HIT exists, there is increasing evidence that acute antithrombin therapy may significantly reduce morbidity and mortality. Among several agents, the direct antithrombins, such as r-hirudin and argatroban, look the most promising for acute treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10375387     DOI: 10.1023/a:1008979010033

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  25 in total

1.  Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor.

Authors:  T Matsuo; K Kario; Y Chikahira; K Nakao; T Yamada
Journal:  Br J Haematol       Date:  1992-11       Impact factor: 6.998

Review 2.  Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

Authors:  B E Lewis; J M Walenga; D E Wallis
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

3.  The 1995 European Society of Cardiology.

Authors:  J J Ferguson
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

4.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  R H Aster
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

5.  Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.

Authors:  G Lefèvre; M Duval; S Gauron; L J Brookman; P E Rolan; T M Morris; A J Piraino; J M Morgan; M Palmisano; P Close
Journal:  Clin Pharmacol Ther       Date:  1997-07       Impact factor: 6.875

Review 6.  Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

7.  A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia.

Authors:  A Tomer
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

8.  Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay.

Authors:  A Greinacher; J Amiral; V Dummel; A Vissac; V Kiefel; C Mueller-Eckhardt
Journal:  Transfusion       Date:  1994-05       Impact factor: 3.157

9.  Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

Authors:  H N Magnani
Journal:  Thromb Haemost       Date:  1993-10-18       Impact factor: 5.249

10.  Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia.

Authors:  F Schiele; A Vuillemenot; P Kramarz; Y Kieffer; T Anguenot; Y Bernard; J P Bassand
Journal:  Am J Hematol       Date:  1995-09       Impact factor: 10.047

View more
  3 in total

Review 1.  Argatroban.

Authors:  Sekar Kathiresan; Jin Shiomura; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2002-02       Impact factor: 2.300

Review 2.  Drug-induced thrombocytopenia in the coronary care unit.

Authors:  N M Patnode; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

Review 3.  Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia.

Authors:  J L Januzzi; I K Jang
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.